Sign in
ADVM-022 Intravitreal Gene Therapy for Neovascular AMD: Phase 1 OPTIC Trial Update
Dante Joseph Pieramici, MD
Annual Meeting Talks
2022
Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2024
Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies
David M. Brown, MD
2021
Category: Retinal Vascular Disease